海洋微生物来源的二倍半萜AsperterpinolB衍生物及合成方法与糖酶应用技术

本发明专利技术公开了海洋微生物来源的二倍半萜Asperterpinol B衍生物及合成方法与糖酶应用。其化学结构如结构式Ⅰ的酯类衍生物、结构式Ⅱ的酰胺类衍生物、结构式Ⅲ的五元环脱水衍生物或结构式Ⅳ的八元环脱水酰胺类衍生物，或其药学上可接受的盐或立体异构体或其前药分子：

Two sesquiterpenoid AsperterpinolB derivatives derived from marine microorganisms and their synthetic methods and application of enzymes

The invention discloses a two sesquiterpenoid Asperterpinol B derivative from marine microorganism and a synthetic method and application of the enzyme. Its chemical structure, such as ester derivatives of structural type I, structural type II amides derivatives, five membered ring dehydration derivatives of structural type III or eight membered ring dehydrated amide derivatives of structural type IV, or pharmaceutically acceptable salt or stereoisomers or their precursor molecules:

【技术实现步骤摘要】
海洋微生物来源的二倍半萜AsperterpinolB衍生物及合成方法与糖酶应用
本专利技术涉及药物化学领域，具体地说，涉及海洋微生物来源的二倍半萜AsperterpinolB(Ze’enetal.,2013)衍生物的制备和其衍生物在α-葡萄糖苷酶抑制剂药物中的应用。
技术介绍
糖尿病(DM)是一种与胰岛素产生和作用异常相关、以高血糖症为主要特征的代谢性疾病。糖尿病主要分为两大类：以胰岛素绝对缺乏为主的Ⅰ型糖尿病及以胰岛素相对缺乏和胰岛素抵抗为主的Ⅱ型糖尿病。随着人们生活水平的提高，糖尿病(DM)对人类健康的日益严重，成为全球性的公共卫生问题。据国际糖尿病联盟(IDF)有关统计表明，2015年全球糖尿病患者约4.15亿人，预计在2040年将达到6.42亿人，糖尿病已成为继肿瘤、心血管疾病之后第三位严重威胁人类健康问题的慢性疾病(IFDdiabetesatlas7thedtion，IDFreport2014and2015)。由于糖尿病还会导致多种慢性急并发症，造成肝、肾及心血管系统的损害，因此解决糖尿病疾病问题刻不容缓。糖尿病与α-葡萄糖苷酶有密切关系。淀粉等碳水化合物类食物在摄入人体后并不能直接被吸收，而是在口腔及胃肠道等各种消化酶的作用下逐步水解成葡萄糖才能被小肠吸收。α-葡萄糖苷酶(AG)是存在于小肠上端粘膜上的消化酶，能水解二糖或者多糖的α-1,4糖苷键，进而将多糖水解成葡萄糖和其他寡糖。α-葡萄糖苷酶抑制剂(AGI)可以竞争性与AG的催化位点结合，抑制AG催化活性，延缓多糖水解成葡萄糖和其他可吸收寡糖，进而使血糖维持在正常水平，防止高血糖和其他并发症的发生(Azumaetal2011)。某些AGI也可非竞争性的与AG的其他位点结合来抑制AG的催化活性。目前市场上治疗糖尿病的药物已经开发，如阿卡波糖、二甲双胍、格列美脲和瑞格列奈等，但是这些药物存在膨胀，腹胀、肠胃气胀、腹泻、肠气囊肿胀的等不良反应，长期服用会导致患者体重增加，易发生低血糖不良反应(Kiharaetal.,1997；Güemesetal.,2016)。糖尿病药物虽然能较好的控制空腹血糖含量，但是不能完全控制餐后血糖的升高。因此人们迫切需要一种能有效降低高血糖，能控制餐后血糖含量，无毒副作用的α-葡萄糖苷酶抑制剂。海洋特殊生态环境中的生物，其代谢产物丰富新颖，是具有新药开发潜力的新领域，拓展新药的重要资源。人们从海洋生物中提取出的海洋天然产物代谢物如萜类、甾醇类、多糖、生物碱、脂肪酸和蛋白质，这些海洋天然产物具有良好的生物活性包括抗菌、抗真菌、抗原生生物、抗结核、抗病毒、抗炎、酶抑制剂等药理活性，对开发高效安全的α-葡萄糖苷酶抑制剂提供重要资源。人们发现萜类具有良好的α-葡萄糖苷酶抑制活性，如从Diospyrosmespiliformis中分离的三萜羽扇豆醇(Mohamedetal.,2009)，从Alpinianigra中分离出的二萜化合物半日花烷二萜(Ghoshetal.,2015)，从海绵分离出来的dysidine(Lietal.,2009；Zhangetal.,2009)都有较好的α-葡萄糖苷酶抑制活性。本专利的AsperterpinolB是一种结构稀有的的5/8/6/6的四环骨架，从红树林内生真菌曲霉菌085242中分离出来的二倍半萜。因此本专利技术对其进行结构修饰，得到一系列对α-葡萄糖苷酶有良好抑制活性的化合物，为临床治疗糖尿病症选择提供了新的药物。
技术实现思路
本专利技术的目的之一是提供一类对糖尿病症具有良好治疗效果的二倍半萜AsperterpinolB的衍生物或其药学上可接受的盐或立体异构体及其前药分子。实现上述目的的技术方案如下：通过与酸酐反应形成酯键或与胺反应形成酰胺键或五元环脱水或八元环脱水形成的二倍半萜AsperterpinolB的衍生物或者其药学上可接受的盐或立体异构体或其前药分子，具有式Ⅰ，Ⅱ，Ⅲ或Ⅳ的结构。通过与酸酐类化合物构成酯键的二倍半萜AsperterpinolB的衍生物中，酸酐化合物优选地，酸酐化学结构可不同，包括，但不局限于，乙酸酐、丙酸酐、丁酸酐、异丁酸酐、正己酸酐、丁二酸酐、戊二酸酐、一氯二氟乙酸酐；通过与胺类化合物构成酰胺键的二倍半萜AsperterpinolB的衍生物中，胺类化学结构可不同，包括，但不局限于，正丙胺，环己胺，呋喃甲胺，苯乙胺，噻吩甲按，环己烯乙胺，噻吩乙胺，对溴苯胺，庚胺，呋喃乙胺，4-(2-氨乙基)吗啉，二烯丙氨，四氢吡咯烷，o-苄基羟胺，四氢异喹啉，N-(3-氨丙基)-吗啡啉，吗啡，1-三氟甲基环戊氨，对甲氧基苯胺，环丙氨，环戊胺，萘胺，3-溴-吡啶-2-氨，3-溴-1-氢吡唑-4-氨。本专利技术的另一目的是提供二倍半萜AsperterpinolB衍生物的合成方法。实现上述目的技术方案如下：通过与酸酐反应形成酯键或与胺反应形成酰胺键或五元环脱水或八元环脱水形成的二倍半萜AsperterpinolB的衍生物。1)二倍半萜AsperterpinolB与酰卤、羧酸、酸酐反应成具有式Ⅰ结构的酯类衍生物。2)结构式为的二倍半萜AsperterpinolB衍生物与胺类化合物反应生成具有结构式Ⅱ的酰胺类衍生物。3)二倍半萜AsperterpinolB在三氟化硼乙醚作用下五元环脱水生成具有式Ⅲ的衍生物。4)结构为的二倍半萜AsperterpinolB先与无水二氯亚砜反应生成中间体酰氯再与胺类化合物反应生成具有式Ⅳ的衍生物。所述胺类化合物为伯胺或仲胺。本专利技术的另一目的是提供一种治疗糖尿病症的药用化合物。实现上述目的技术方案如下：一种治疗糖尿病症的药用衍生物，其药学活性成份通过与酸酐反应形成酯键或与胺反应形成酰胺键或五元环脱水或八元环脱水形成的二倍半萜AsperterpinolB的衍生物或者其药学上可接受的盐或立体异构体或其前药分子。本专利技术的另一目的是提供上述二倍半萜AsperterpinolB的衍生物或者其药学上可接受的盐或立体异构体或其前药分子的应用。实现上述目的技术方案如下：上述通过通过与酸酐反应形成酯键或与胺反应形成酰胺键或五元环脱水或八元环脱水形成的二倍半萜AsperterpinolB的衍生物或者其药学上可接受的盐或立体异构体或其前药分子在制备对α-葡萄糖苷酶抑制剂药物中的应用。本专利技术通过将二倍半萜AsperterpinolB进行衍生化，得到新的化学实体，得到的新化合物具有很好的治疗糖尿病症的效果，为临床治疗选择提供了新的药物。具体实施方式通过以下实施例对本专利技术具体实施方法进行描述，但该实施例并非用于限制本专利技术的保护范围。实施例1AsB-1:(2aS,6aS,6bS,12S,12aS,13R,13aS,Z)-2a,5,5,9,12,13a-hexamethyl-2,2a,3,4,5,6,6a,6b,7,8,12,12a,13,13a-tetradecahydro-1H-cyclopenta[4,5]cycloocta[1,2-a]naphthalen-13-ol的合成实验步骤：称取AsB(38.7mg，0.103mmol，1eq)于50ml的圆底烧瓶，加入2ml二氯甲烷溶解，1ml注射器滴加三氟化硼乙醚(质量分数为46.5％-49.5％)(50ul，0.135mmol，1.3eq本文档来自技高网...

【技术保护点】
1.二倍半萜Asperterpinol B衍生物，其化学结构如结构式Ⅰ的酯类衍生物、结构式Ⅱ的酰胺类衍生物、结构式Ⅲ的五元环脱水衍生物或结构式Ⅳ的八元环脱水酰胺类衍生物，或其药学上可接受的盐或立体异构体或其前药分子：

【技术特征摘要】
1.二倍半萜AsperterpinolB衍生物，其化学结构如结构式Ⅰ的酯类衍生物、结构式Ⅱ的酰胺类衍生物、结构式Ⅲ的五元环脱水衍生物或结构式Ⅳ的八元环脱水酰胺类衍生物，或其药学上可接受的盐或立体异构体或其前药分子：R0：为X取代的碳原子数为1-10的烷烃、烯烃、炔烃、环烷烃或苯基，X为H、Cl、Br、F、I、CN、NO2、CF3、OH、OCH3、COOH或COOCH3；R1、R2：为X取代的碳原子数为1-10的烷烃、烯烃、炔烃、环烷烃、N/O/S杂环或苯基，X为H、Cl、Br、F、I、CN、NO2、CF3、OH、OCH3、COOH或COOCH3。2.根据权利要求1所述的二倍半萜AsperterpinolB衍生物，其特征是，在结构式Ⅰ中，R0为CH2CH2CH2CH2CH3、CH2CH2CH3、CH2CH3、CH(CH3)2、CH3、CF2Cl、CH2CH2COOH或CH2CH2CH2COOH；在结构式Ⅱ中，R1为H，R2为：在结构式Ⅳ中，R1+R2为各种环胺，包括或R1＝R2为各种烯烃，包括3.根据权利要求1所述的二倍半萜AsperterpinolB衍生物，其特征是，所述衍生化合物选自以下：AsB-1:(2aS,6aS,6bS,12S,12aS,13R,13aS,Z)-2a,5,5,9,12,13a-hexamethyl-2,2a,3,4,5,6,6a,6b,7,8,12,12a,13,13a-tetradecahydro-1H-cyclopenta[4,5]cycloocta[1,2-a]naphthalen-13-ol.AsB-S1:(2aS,6aS,6bS,11R,12R,12aS,13R,13aS,Z)-13-hydroxy-2a,5,5,9,12,13a-hexamethyl-2,2a,3,4,5,6,6a,6b,7,8,10,11,12,12a,13,13a-hexadecahydro-1H-cyclopenta[4,5]cycloocta[1,2-a]naphthalen-11-ylacetate.AsB-S2:(2aS,6aS,6bS,11R,12R,12aS,13R,13aS,Z)-13-hydroxy-2a,5,5,9,12,13a-hexamethyl-2,2a,3,4,5,6,6a,6b,7,8,10,11,12,12a,13,13a-hexadecahydro-1H-cyclopenta[4,5]cycloocta[1,2-a]naphthalen-11-ylbutyrate.AsB-S3:4-(((2aS,6aS,6bS,11R,12R,12aS,13R,13aS,Z)-13-hydroxy-2a,5,5,9,12,13a-hexamethyl-2,2a,3,4,5,6,6a,6b,7,8,10,11,12,12a,13,13a-hexadecahydro-1H-cyclopenta[4,5]cycloocta[1,2-a]naphthalen-11-yl)oxy)-4-oxobutanoicacid.AsB-S4:(2aS,6aS,6bS,11R,12R,12aS,13R,13aS,Z)-13-hydroxy-2a,5,5,9,12,13a-hexamethyl-2,2a,3,4,5,6,6a,6b,7,8,10,11,12,12a,13,13a-hexadecahydro-1H-cyclopenta[4,5]cycloocta[1,2-a]naphthalen-11-ylpropionate.AsB-S5:5-(((2aS,6aS,6bS,11R,12R,12aS,13R,13aS,Z)-13-hydroxy-2a,5,5,9,12,13a-hexamethyl-2,2a,3,4,5,6,6a,6b,7,8,10,11,12,12a,13,13a-hexadecahydro-1H-cyclopenta[4,5]cycloocta[1,2-a]naphthalen-11-yl)oxy)-5-oxopentanoicacid.AsB-S6:(2aS,6aS,6bS,11R,12R,12aS,13R,13aS,Z)-13-hydroxy-2a,5,5,9,12,13a-hexamethyl-2,2a,3,4,5,6,6a,6b,7,8,10,11,12,12a,13,13a-hexadecahydro-1H-cyclopenta[4,5]cycloocta[1,2-a]naphthalen-11-ylhexanoate.AsB-S9:(2aS,6aS,6bS,11R,12R,12aS,13R,13aS,Z)-13-hydroxy-2a,5,5,9,12,13a-hexamethyl-2,2a,3,4,5,6,6a,6b,7,8,10,11,12,12a,13,13a-hexadecahydro-1H-cyclopenta[4,5]cycloocta[1,2-a]naphthalen-11-ylisobutyrate.AsB-S10:(2aS,6aS,6bS,11R,12R,12aS,13R,13aS,Z)-13-hydroxy-2a,5,5,9,12,13a-hexamethyl-2,2a,3,4,5,6,6a,6b,7,8,10,11,12,12a,13,13a-hexadecahydro-1H-cyclopenta[4,5]cycloocta[1,2-a]naphthalen-11-yl2-chloro-2,2-difluoroacetate.AsB-n1:(2aS,6aS,6bS,11R,12R,12aS,13R,13aS,Z)-13-hydroxy-2a,5,5,9,12,13a-hexamethyl-2,2a,3,4,5,6,6a,6b,7,8,10,11,12,12a,13,13a-hexadecahydro-1H-cyclopenta[4,5]cycloocta[1,2-a]naphthalen-11-yl4-oxo-4-(propylamino)butanoate.AsB-n2:(2aS,6aS,6bS,11R,12R,12aS,13R,13aS,Z)-13-hydroxy-2a,5,5,9,12,13a-hexamethyl-2,2a,3,4,5,6,6a,6b,7,8,10,11,12,12a,13,13a-hexadecahydro-1H-cyclopenta[4,5]cycloocta[1,2-a]naphthalen-11-yl4-(cyclohexylamino)-4-oxobutanoate.AsB-n3:(2aS,6aS,6bS,9Z,11R,12R,12aZ,13aS)-2a,5,5,9,12,13a-hexamethyl-2,2a,3,4,5,6,6a,6b,7,8,10,11,12,13a-tetradecahydro-1H-cyclopenta[4,5]cycloocta[1,2-a]naphthalen-11-yl4-oxo-4-(propylamino)butanoate.AsB-n4:(2aS,6aS,6bS,11R,12R,12aS,13R,13aS,Z)-13-hydroxy-2a,5,5,9,12,13a-hexamethyl-2,2a,3,4,5,6,6a,6b,7,8,10,11,12,12a,13,13a-hexadecahydro-1H-cyclopenta[4,5]cycloocta[1,2-a]naphthalen-11-yl4-((furan-2-ylmethyl)amino)-4-oxobutanoate.AsB-n5:(2aS,6aS,6bS,11R,12R,12aS,13R,13aS,Z)-13-hydroxy-2a,5,5,9,12,13a-hexamethyl-2,2a,3,4,5,6,6a,6b,7,8,10,11,12,12a,13,13a-hexadecahydro-1H-cyclopenta[4,5]cycloocta[1,2-a]naphthalen-11-yl4-oxo-4-(phenethylamino)butanoate.AsB-n6:(2aS,6aS,6bS,11R,12R,12aS,13R,13aS,Z)-13-hydroxy-2a,5,5,9,12,13a-hexamethyl-2,2a,3,4,5,6,6a,6b,7,8,10,11,12,12a,13,13a-hexadecahydro-1H-cyclopenta[4,5]cycloocta[1,2-a]naphthalen-11-yl4-oxo-4-((thiophen-2-ylmethyl)amino)butanoate.AsB-n7:(2aS,6aS,6bS,11R,12R,12aS,13R,13aS,Z)-13-hydroxy-2a,5,5,9,12,13a-hexamethyl-2,2a,3,4,5,6,6a,6b,7,8,10,11,12,12a,13,13a-hexadecahydro-1H-cyclopenta[4,5]cycloocta[1,2-a]naphthalen-11-yl4-((2-(cyclohex-1-en-1-yl)ethyl)amino)-4-oxobutanoate.AsB-n8:(2aS,6aS,6bS,11R,12R,12aS,13R,13aS,Z)-13-hydroxy-2a,5,5,9,12,13a-hexamethyl-2,2a,3,4,5,6,6a,6b,7,8,10,11,12,12a,13,13a-hexadecahydro-1H-cyclopenta[4,5]cycloocta[1,2-a]naphthalen-11-yl4-oxo-4-((2-(thiophen-2-yl)ethyl)amino)butanoate.AsB-n9:(2aS,6aS,6bS,11R,12R,12aS,13R,13aS,Z)-13-hydroxy-2a,5,5,9,12,13a-hexamethyl-2,2a,3,4,5,6,6a,6b,7,8,10,11,12,12a,13,13a-hexadecahydro-1H-cyclopenta[4,5]cycloocta[1,2-a]naphthalen-11-yl4-((4-bromophenyl)amino)-4-oxobutanoate.AsB-n10:(2aS,6aS,6bS,11R,12R,12aS,13R,13aS,Z)-13-hydroxy-2a,5,5,9,12,13a-hexamethyl-2,2a,3,4,5,6,6a,6b,7,8,10,11,12,12a,13,13a-hexadecahydro-1H-cyclopenta[4,5]cycloocta[1,2-a]naphthalen-11-yl4-(heptylamino)-4-oxobutanoate.AsB-n11:(2aS,6aS,6bS,11R,12R,12aS,13R,13aS,Z)-13-hydroxy-2a,5,5,9,12,13a-hexamethyl-2,2a,3,4,5,6,6a,6b,7,8,10,11,12,12a,13,13a-hexadecahydro-1H-cyclopenta[4,5]cycloocta[1,2-a]naphthalen-11-yl4-((2-(furan-2-yl)ethyl)amino)-4-oxobutanoate.AsB-n12:(2aS,6aS,6bS,11R,12R,12aS,13R,13aS,Z)-13-hydroxy-2a,5,5,9,12,13a-hexamethyl-2,2a,3,4,5,6,6a,6b,7,8,10,11,12,12a,13,13a-hexadecahydro-1H-cyclopenta[4,5]cycloocta[1,2-a]naphthalen-11-yl4-((2-morpholinoethyl)amino)-4-oxobutanoateAsB-n13:(2aS,6aS,6bS,11R,12R,12aS,13R,13aS,Z)-13-hydroxy-2a,5,5,9,12,13a-hexamethyl-2,2a,3,4,5,6,6a,6b,7,8,10,11,12,12a,13,13a-hexadecahydro-1H-cyclopenta[4,5]cycloocta[1,2-a]naphthalen-11-yl4-(diallylamino)-4-oxobutanoate.AsB-n14:(2aS,6aS,6bS,11R,12R,12aS,13R,13aS,Z)-13-hydroxy-2a,5,5,9,12,13a-hexamethyl-2,2a,3,4,5,6,6a,6b,7,8,10,11,12,12a,13,13a-hexadecahydro-1H-cyclopenta[4,5]cycloocta[1,2-a]naphthalen-11-yl4-oxo-4-(pyrrolidin-1-yl)butanoate.AsB-n15:(2aS,6aS,6bS,11R,12R,12aS,13R,13aS,Z)-13-hydroxy-2a,5,5,9,12,13a-hexamethyl-2,2a,3,4,5,6,6a,6b,7,8,10,11,12,12a,13,13a-hexadecahydro-1H-cyclopenta[4,5]cycloocta[1,2-a]naphthalen-11-yl4-((benzyloxy)amino)-4-oxobutanoate.AsB-n16:(2aS,6aS,6bS,11R,12R,12aS,13R,13aS,Z)-13-hydroxy-2a,5,5,9,12,13a-hexamethyl-2,2a,3,4,5,6,6a,6b,7,8,10,11,12,12a,13,13a-hexadecahydro-1H-cyclopenta[4,5]cycloocta[1,2-a]naphthalen-11-yl4-(3,4-dihydroisoquinolin-2(1H)-yl)-4-oxobutanoate.AsB-n17:(2aS,6aS,6bS,11R,12R,12aS,13R,13aS,Z)-13-hydroxy-2a,5,5,9,12,13a-hexamethyl-2,2a,3,4,5,6,6a,6b,7,8,10,11,12,12a,13,13a-hexadecahydro-1H-cyclopenta[4,5]cycloocta[1,2-a]naphthalen-11-yl7-morpholino-4-oxoheptanoateAsB-n18:(2aS,6aS,6bS,11R,12R,12aS,13R,13aS,Z)-13-hydroxy-2a,5,5,9,12,13a-hexamethyl-2,2a,3,4,5,6,6a,6b,7,8,10,11,12,12a,13,13a-hexadecahydro-1H-cyclopenta[4,5]cycloocta[1,2-a]naphthalen-11-yl4-morpholino-4-oxobutanoate.AsB-n19:(2aS,6aS,6bS,11R,12R,12aS,13R,13aS,Z)-13-hydroxy-2a,5,5,9,12,13a-hexamethyl-2,2a,3,4,5,6,6a,6b,7,8,10,11,12,12a,13,13a-hexadecahydro-1H-cyclopenta[4,5]cycloocta[1,2-a]naphthalen-11-yl4-oxo-4-(2-(trifluoromethyl)pyrrolidin-1-yl)butanoate.AsB-n20:(2aS,6aS,6bS,11R,12R,12aS,13R,13aS,Z)-13-hydroxy-2a,5,5,9,12,13a-hexamethyl-2,2a,3,4,5,6,6a,6b,7,8,10,11,12,12a,13,13a-hexadecahydro-1H-cyclopenta[4,5]cycloocta[1,2-a]naphthalen-11-yl4-((4-methoxyphenyl)amino)-4-oxobutanoate.AsB-n21:(2aS,6aS,6bS,11R,12R,12aS,13R,13aS,Z)-13-hydroxy-2a,5,5,9,12,13a-hexamethyl-2,2a,3,4,5,6,6a,6b,7,8,10,11,12,12a,13,13a-hexadecahydro-1H-cyclopenta[4,5]cycloocta[1,2-a]naphthalen-11-yl4-(cyclopropylamino)-4-oxobutanoateAsB-n22:(2aS,6aS,6bS,11R,12R,12aS,13R,13aS,Z)-13-hydroxy-2a,5,5,9,12,13a-hexamethyl-2,2a,3,4,5,6,6a,6b,7,8,10,11,12,12a,13,13a-hexadecahydro-1H-cyclopenta[4,5]cycloocta[1,2-a]naphthalen-11-yl4-(cyclopentylamino)-4-oxobutanoate.AsB-n23:(2aS,6aS,6bS,11R,12R,12aS,13R,13aS,Z)-13-hydroxy-2a,5,5,9,12,13a-hexamethyl-2,2a,3,4,5,6,6a,6b,7,8,10,11,12,12a,13,13a-hexadecahydro-1H-cyclopenta[4,5]cycloocta[1,2-a]naphthalen-11-yl4-(naphthalen-1-ylamino)-4-oxobutanoate.AsB-n24:(2aS,6aS,6bS,11R,12R,12aS,13R,13aS,Z)-13-hydroxy-2a,5,5,9,12,13a-hexamethyl-2,2a,3,4,5,6,6a,6b,7,8,10,11,12,12a,13,13a-hexadecahydro-1H-cyclopenta[4,5]cycloocta[1,2-a]naphthalen-11-yl4-((3-bromopyridin-2-yl)amino)-4-oxobutanoate.AsB-n25:(2aS,6aS,6bS,11R,12R,12aS,13R,13aS,Z)-13-hydroxy-2a,5,5,9,12,13a-hexamethyl-2,2a,3,4,5,6,6a,6b,7,8,10,11,12,12a,13,13a-hexadecahydro-1H-cyclopenta[4,5]cycloocta[1,2-a]naphthalen-11-yl-4-((4-bromo-1H-pyrazol-3-yl)amino)-4-oxobutanoate。4.根...

【专利技术属性】
技术研发人员：龙玉华，李婷妹，佘志刚，范炜隆，温世彤，颜樟元，郭惠娴，黄翠莹，蒋腊生，
申请(专利权)人：华南师范大学，
类型：发明
国别省市：广东,44